Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hanefeld

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
Diabetologia|July 14, 1998
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individualsT Temelkova-Kurktschiev, C Koehler, F Schaper, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 20, 2011
Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitusB Engler, C Koehler, C Hoffmann, et al.
Pharmacology & Therapeutics|January 27, 2009
An update on preventive and regenerative therapies in diabetes mellitusM Reimann, E Bonifacio, M Solimena, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 19, 2009
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patientsA Pfützner, T Schöndorf, M Hanefeld, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 24, 2007
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT studyA Pfützner, M Hanefeld, G Lübben, et al.
Acta Diabetologica|October 3, 2002
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat massS Fischer, M Hanefeld, S M Haffner, et al.
Arzneimittel-Forschung|April 1, 1990
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemiaS Fischer, M Hanefeld, P D Lang, et al.
Diabetologia|December 1, 1996
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-upM Hanefeld, S Fischer, U Julius, et al.
Journal of Lipid Research|October 1, 1996
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approachJ Pietzsch, B Wiedemann, U Julius, et al.
Diabetes, Obesity & Metabolism|March 13, 2015
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)G Schernthaner, S Durán-Garcia, M Hanefeld, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Diabetologia|July 14, 1998
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individualsT Temelkova-Kurktschiev, C Koehler, F Schaper, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|January 20, 2011
Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitusB Engler, C Koehler, C Hoffmann, et al.
Pharmacology & Therapeutics|January 27, 2009
An update on preventive and regenerative therapies in diabetes mellitusM Reimann, E Bonifacio, M Solimena, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|February 19, 2009
Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patientsA Pfützner, T Schöndorf, M Hanefeld, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|October 24, 2007
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT studyA Pfützner, M Hanefeld, G Lübben, et al.
Acta Diabetologica|October 3, 2002
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat massS Fischer, M Hanefeld, S M Haffner, et al.
Arzneimittel-Forschung|April 1, 1990
Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemiaS Fischer, M Hanefeld, P D Lang, et al.
Diabetologia|December 1, 1996
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-upM Hanefeld, S Fischer, U Julius, et al.
Journal of Lipid Research|October 1, 1996
Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: a stable isotope approachJ Pietzsch, B Wiedemann, U Julius, et al.
Diabetes, Obesity & Metabolism|March 13, 2015
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)G Schernthaner, S Durán-Garcia, M Hanefeld, et al.
Pageof 23